dc.contributor.author | RASMUSSEN, S. | |
dc.contributor.author | GARBER, A. J. | |
dc.contributor.author | BHARGAVA, A. | |
dc.contributor.author | DHARMALINGAM, M. | |
dc.contributor.author | SKJOTH, T. V. | |
dc.contributor.author | Satman, I. | |
dc.contributor.author | PHILIS-TSIMIKAS, A. | |
dc.contributor.author | DEL PRATO, S. | |
dc.date.accessioned | 2021-03-05T22:00:33Z | |
dc.date.available | 2021-03-05T22:00:33Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | PHILIS-TSIMIKAS A., DEL PRATO S., Satman I., BHARGAVA A., DHARMALINGAM M., SKJOTH T. V. , RASMUSSEN S., GARBER A. J. , "Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents", DIABETES OBESITY & METABOLISM, cilt.15, ss.760-766, 2013 | |
dc.identifier.issn | 1462-8902 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_db8d8eb9-bc3c-436f-989c-6efe6880bfe2 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/144726 | |
dc.identifier.uri | https://doi.org/10.1111/dom.12115 | |
dc.description.abstract | Aim: The efficacy and safety of insulin degludec (IDeg), a new basal insulin with an ultra-long duration of action, was compared to sitagliptin (Sita) in a 26-week, open-label trial. | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | ENDOKRİNOLOJİ VE METABOLİZMA | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Endokrinoloji ve Metabolizma Hastalıkları | |
dc.title | Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents | |
dc.type | Makale | |
dc.relation.journal | DIABETES OBESITY & METABOLISM | |
dc.contributor.department | Scripps Whittier Diabet Inst , , | |
dc.identifier.volume | 15 | |
dc.identifier.issue | 8 | |
dc.identifier.startpage | 760 | |
dc.identifier.endpage | 766 | |
dc.contributor.firstauthorID | 17929 | |